Norfolk Southern Corporation vs Novavax Inc — how do they compare? Norfolk Southern Corporation trades at $335.84 (market cap $75.15B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Norfolk Southern Corporation is far larger — about 57.4× Novavax Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NSC | NVAX | |
|---|---|---|
Market Cap | $75.15B | $1.31B |
Sector | Technology | Health |
52-Week High | $350.66 | $11.19 |
52-Week Low | $272.35 | $6.22 |
Enterprise Value | $90.70B | $889.30M |
Dividend Yield | 1.61% | — |
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $335.41, up 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $369.67. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.52 exceeding expectations, driven by record revenue and volume growth. A pending merger with Union Pacific and a recent dividend declaration highlight ongoing corporate activity.
The outlook is positive, supported by strong operational performance and favorable industry trends, though risks include integration challenges from the merger, premium valuation metrics, and potential economic headwinds affecting freight demand. Investor sentiment is mixed, with analysts predominantly holding a neutral to bullish stance.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Latest headlines on both assets
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →